Form 4: CONMED CEO Pat Beyer Receives $1M Equity Award
Statement of Changes in Beneficial Ownership
CONMED Corporation CEO Pat Beyer was granted 28,145 restricted stock units as part of an approved equity incentive plan.
Summary
- CEO Pat Beyer received a grant of 28,145 Restricted Stock Units (RSUs) on April 1, 2026.
- The grant represents a target value of $1 million as approved by the Board of Directors on March 23, 2026.
- The RSUs vest in three equal annual tranches over a three-year period.
- A two-year post-vest holding period applies to net after-tax shares following each vesting event.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a routine administrative filing regarding executive compensation that does not materially alter the company's financial outlook.
Positives
- Aligns executive compensation with long-term shareholder interests through a multi-year vesting schedule.
- Includes a mandatory two-year post-vest holding period, encouraging long-term commitment from leadership.
Negatives
- Results in minor dilution to existing shareholders upon the eventual conversion of RSUs to common stock.
Risks
- Potential for executive turnover if performance targets or retention incentives are not met.
Future Outlook
The grant is structured to vest over three years, indicating a focus on long-term executive retention and performance alignment through 2029.
Management Comments
- The Board of Directors approved an additional equity award for the CEO to be granted in the form of RSUs.
Industry Context
StockSavvy.ai notes that this grant is consistent with standard corporate governance practices in the medical device sector, where long-term equity incentives are used to retain key leadership talent.
Comparison to Industry Standards
- The use of a three-year vesting schedule is standard practice for executive compensation in the S&P 400/Mid-cap space.
- The inclusion of a post-vest holding period is a best-practice governance feature that exceeds the requirements of many peer companies.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Executive Compensation Policy | Implementation of a 2-year post-vest holding period for CEO equity awards. | 04/01/2026 | Increases alignment between executive interests and long-term shareholder value. |
Stakeholder Impact
- Shareholders: Minor dilution impact.
- CEO: Increased long-term incentive and retention.
Next Steps
- Vesting of the first tranche of RSUs scheduled for 2027.
Key Dates
| Date | Description |
|---|---|
| 03/23/2026 | Board of Directors approval of the equity award. |
| 04/01/2026 | Grant date of the RSUs and commencement of the vesting schedule. |
| 04/02/2026 | Filing date of the Form 4. |
| 04/01/2036 | Expiration date of the RSU grant. |
Keywords
CONMED, CNMD, Executive Compensation, Form 4, Insider Trading, Equity Grant
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.